How a Company Books Record Revenue and Still Burns Cash: Champions Oncology CSBR FY2026 10-K
The Hook
Champions Oncology $CSBR just booked the biggest revenue year in its history and burned cash doing it. Fiscal 2026, the year ended April 30, 2026, brought in $59.425 million, up 4.4% and a company record. Operating income went the other way, from positive $4.553 million to negative $1.140 million. And the cash line moved almost twice as hard as the earnings line: operating cash flow swung from positive $7.386 million to negative $4.472 million, an $11.858 million reversal in twelve months.
The 10-K filed on July 27, 2026 says exactly where the money went, and most of it is not in the income statement. It is in one line of the cash flow statement. Deferred revenue fell $6.615 million in fiscal 2026, against a $3.349 million increase the year before, a $9.964 million swing that is 84% of the entire cash reversal on its own. Champions recognized $30.717 million of revenue out of its customer prepayment balance and only added $24.102 million of new prepayments back in. The record top line was, in part, the backlog being converted into revenue. Management's own words for the cause: "lower bookings."
Company Snapshot
Champions Oncology is a preclinical research organization. Pharmaceutical and biotech companies developing cancer drugs pay it to run studies that predict whether a drug will work, using a bank of patient-derived tumor models, human tumors implanted into immune-deficient mice, that the company calls its TumorGraft Technology Platform. It also licenses access to the genomic data behind those models and sells a bioinformatics package called Lumin. One reportable segment, four operating subsidiaries, and 214 full-time employees as of July 15, 2026. It is a microcap: the 10-K cover reports a public float of $28.6 million as of October 31, 2025.
This is the FY2026 annual report, a 10-K covering the year ended April 30, 2026, filed July 27, 2026. Every figure below comes from that filing or from the comparative prior-year figures in it, except where a market price is named and sourced.
The Financial Story
Four years of this company in three lines:
| Fiscal year (ended Apr 30) | Revenue | Operating income | Operating cash flow |
|---|---|---|---|
| FY2023 | $53.870M | -$5.256M | +$3.972M |
| FY2024 | $50.155M | -$7.356M | -$6.137M |
| FY2025 | $56.944M | +$4.553M | +$7.386M |
| FY2026 | $59.425M | -$1.140M | -$4.472M |
FY2025 now looks like the outlier, not the trend. It was the only profitable year in four, and FY2026 gave back the operating profit and then some.
The 4.4% growth is one number covering three very different businesses. The disaggregation in the revenue note:
| Revenue line | FY2025 | FY2026 | Change |
|---|---|---|---|
| Pharmacology services | $48.585M | $57.133M | +$8.548M (+17.6%) |
| TOS data license revenue | $4.676M | $0.764M | -$3.912M (-83.7%) |
| Other TOS revenue | $3.683M | $1.528M | -$2.155M (-58.5%) |
| Total oncology revenue | $56.944M | $59.425M | +$2.481M (+4.4%) |
The lab-services business grew 17.6%. The data licensing business fell 83.7%, because, per the filing, FY2025 "primarily reflected a significant data license transaction with a single customer" and FY2026 did not include a comparable deal. Other TOS revenue, mostly flow cytometry and Lumin software, fell 58.5% as the company shifted investment away from flow cytometry. So $6.067 million of high-margin license and software revenue was replaced by $8.548 million of lab work that costs real money to deliver. That mix shift, not a pricing problem, is what happened to the gross margin.
Gross profit was flat in dollars. The damage was operating expense. Cost of oncology revenue rose from 49.9% of revenue to 52.0%, so gross profit went from $28.555 million to $28.525 million, down $30 thousand on $2.481 million of extra revenue. Everything below that line is where the $5.693 million operating swing came from:
| Cost line | FY2025 | FY2026 | Change | % |
|---|---|---|---|---|
| Cost of oncology revenue | $28.389M | $30.900M | +$2.511M | +8.8% |
| Research and development | $6.825M | $9.084M | +$2.259M | +33.1% |
| General and administrative | $9.339M | $11.152M | +$1.813M | +19.4% |
| Sales and marketing | $7.545M | $9.318M | +$1.773M | +23.5% |
| Loss on disposal of equipment | $0.293M | $0.111M | -$0.182M | -62.1% |
| Total costs and operating expenses | $52.391M | $60.565M | +$8.174M | +15.6% |
Revenue added $2.481 million. Costs added $8.174 million. Research and development, sales and marketing, and general and administrative together went from $23.709 million to $29.554 million, up $5.845 million or 24.7%, on a top line that grew 4.4%.
The detail matters. Inside R&D, outside services went from roughly $0.59 million to roughly $2.27 million while mice costs fell from roughly $0.55 million to roughly $0.13 million: this is sequencing and data-platform spend, not animal work. Inside cost of revenue, the increase was "primarily driven by higher outsourced laboratory costs associated with the expansion of our radiopharmacology services," capability the company says it brought in-house during fiscal 2026 and expects to cost less in fiscal 2027. G&A rose on IT costs, stock-based compensation, which more than doubled from $0.654 million to $1.237 million, and "costs associated with changes in executive leadership."
And the headcount tells you the shape of the year. Total full-time staff went from 213 to 214, essentially flat, but the mix moved: sales and marketing from 32 people to 45, research and lab operations from 159 down to 149. The company added thirteen salespeople, subtracted ten scientists, spent $1.773 million more on sales and marketing, and bookings still fell.
Now the cash. The $11.858 million operating cash flow reversal splits roughly into two halves. About $5.3 million is the earnings swing itself once non-cash items are netted off: net income went from positive $4.701 million to negative $1.175 million, partly cushioned by higher stock compensation and a swing in the credit-loss provision. The other $6.541 million is working capital, and it is almost entirely one line:
Deferred revenue opened FY2026 at $15.443 million. Additions were $24.102 million, down from $29.973 million the year before, a 19.6% drop. Revenue recognized out of it was $30.717 million, up from $26.624 million. Closing balance: $8.828 million. The balance fell 42.8% in one year. That is a $6.615 million use of cash against a $3.349 million source last year, a $9.964 million swing, which is larger than the $6.541 million total working-capital move it sits inside, because payables partly offset it. Two other working-capital lines moved: accounts receivable consumed $2.002 million versus $1.436 million last year, and accounts payable provided $2.558 million versus consuming $1.749 million last year. Note what that second one means. The single largest offset preventing the cash number from being worse was the company paying its own suppliers more slowly. Accounts payable on the balance sheet rose from $4.248 million to $6.903 million.
The receivable line has a tell of its own. Billed receivables actually fell slightly, from $6.835 million to $6.707 million. Unbilled receivables, revenue recognized ahead of the invoice, rose from $5.398 million to $7.528 million. Revenue is being recognized in front of both the billing and the cash.
Balance sheet: thin, but not levered. Cash fell from $9.785 million to $4.872 million. Total assets fell from $32.344 million to $26.989 million. Current assets of $19.219 million against current liabilities of $19.922 million leaves negative working capital of $703 thousand, a figure the company tags explicitly in its own filing. Stockholders' equity is $3.939 million against an accumulated deficit of $81.067 million. There is no bank debt and no credit facility: finance lease liabilities total $86 thousand, operating lease liabilities are $4.512 million, and the filing states "we have no off-balance sheet debt or similar obligations." Federal net operating loss carryforwards stand at $41.0 million with a $16.364 million valuation allowance, so the tax shield is real but unrecognized.
Management does not include a going-concern qualification. It states that cash on hand "together with expected cash flows from operations, are adequate to fund operations through at least August 2027." Read that carefully: the runway depends on operations turning cash-positive again, because $4.872 million of cash does not survive another $4.472 million year on its own.
One subsequent event belongs in the same paragraph. On June 5, 2026, five weeks after year end, the company amended the operating lease on its Rockville, Maryland office and lab and extended the term through March 31, 2037. It expects to add roughly $6.3 million to right-of-use assets and lease liabilities, and roughly $16.9 million to future contractual minimum lease payments. A company holding $4.9 million of cash with negative working capital just committed to eleven more years of that facility.
Valuation: what the market is paying, and what would have to be true
Champions Oncology closed at $5.46 on July 29, 2026, for a market capitalization of about $75.9 million on 13.89 million shares (source: stockanalysis.com, quote dated July 29, 2026). Net of $4.872 million of cash and $0.086 million of finance leases from the filing, enterprise value is roughly $71.1 million, or about 1.2 times FY2026 revenue. The same source lists no analyst count and no price target: this company has no visible sell-side coverage.
A discounted cash flow model would be false precision here, so this brief does not run one. The honest reason: FY2026 EBITDA, taken as operating income plus the $1.377 million of depreciation and amortization in the filing, is $0.237 million. On a base that small, essentially all of a DCF's value sits in the terminal assumption, and the operating cash flow line has swung by $10.1 million, $13.5 million and $11.9 million in the last three year-over-year comparisons. Any projection would be an opinion wearing a spreadsheet.
What is defensible is a "what has to be true" bridge, using only filing figures. At FY2026's 48.0% gross margin, restoring FY2025's $4.553 million of operating income without cutting a dollar of cost would take roughly $11.9 million of additional revenue, about 20% growth. Coming the other way, holding revenue flat, it would take about a 19% reduction in the $29.554 million of research, sales and administrative spend. The market is currently paying about 1.2 times revenue and 2.5 times gross profit for the chance that one of those happens.
The one number to watch is not revenue. It is deferred revenue additions, $24.102 million this year against $29.973 million last year. That line is the closest thing in the filing to a bookings disclosure, and it leads the income statement by a year.
Risks
The concentration risk got materially worse and is easy to miss. One customer was 24% of total revenue in FY2026, up from 13% in FY2025 for the same customer, and that customer represented 25% of accounts receivable at year end. Pharmacology services grew $8.548 million; a customer moving from 13% to 24% of a $59.4 million top line accounts for more than all of it. This was not broad growth. Meanwhile the FY2025 data-license revenue that vanished was itself, per the filing, one significant transaction with a single customer. Two consecutive years, two different single-customer stories.
The rest is the ordinary shape of microcap risk, stated plainly in the filing: the company needs "to generate revenues to offset our operating costs" to become sustainably profitable; customer demand depends on pharmaceutical and biotech research budgets, which the risk factors acknowledge could reduce "potential for new bookings"; and the $41.0 million of net operating losses could be restricted by an ownership change under the tax code. Cash of $4.9 million against a $4.5 million annual operating outflow is a genuine constraint, not a rounding error, and the filing notes that if capital is needed "there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all."
The Bottom Line
Champions Oncology's record year was not built the way a record year is supposed to be built. Its core lab business genuinely grew 17.6%, but the profitable license and software revenue that funded the margin disappeared, operating costs rose more than three times faster than revenue, and the cash that would normally arrive up front from customers did not: deferred revenue additions fell 19.6% and the balance drained by 42.8%. That last fact is the one that matters, because prepayments are the leading indicator and revenue is the lagging one. The FY2026 income statement was partly paid for by the FY2025 balance sheet.
The framework for the next four quarters is simple. Watch deferred revenue additions and the closing deferred balance in each 10-Q before you look at revenue. Watch whether cost of oncology revenue comes back under 50% now that radiopharmacology has moved in-house. Watch whether the 24% customer stays. And watch cash against a $4.9 million starting balance and a stated runway that assumes operations turn.
All figures are from Champions Oncology's FY2026 Form 10-K (fiscal year ended April 30, 2026, filed July 27, 2026) unless otherwise attributed. The price and market capitalization are from stockanalysis.com as of the July 29, 2026 close. This is analysis, not investment advice, and contains no price target.
Every number above was pulled from the original XBRL in the SEC filing itself, through the RoboSystems SEC Shared Repository: structured filing data for every public company that files. No analyst covers this company. The pipeline that read this 10-K reads any of them. robosystems.ai/pricing